Overview

• U.S. breath alcohol tester maker's Q1 revenue rose 1% from a year earlier

• Net loss narrowed as gross margin improved to 43% on higher pricing and favorable product mix

• Company secured $500,000 loan from Chairman and CFO in May 2026

Outlook

• Company expects initial SpinDetect product to enable oral fluid delta-9-THC detection, followed by multi-drug panel

• Lifeloc does not anticipate further technical breakthroughs required before SpinDetect commercialization

• Company plans to expand SpinDetect platform to additional drug and non-drug applications, including food pathogen detection

Result Drivers

• MARGIN IMPROVEMENT - Co said gross margin rose to 43% from 40% last year, due to increased pricing and a favorable product mix

• R&D SPENDING - Research and development investment declined but remained high, mainly for SpinDetect analyzer development

• PRODUCT MIX - Market share gains attributed to Easycal automated calibration station and strength in L-series alcohol detection devices

Company press release: ID:nACSNppgWa

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.